May 30, 2017 / 5:11 AM / 2 months ago

BRIEF-Molecular Partners provides additional details on clinical studies of MP0250​

1 Min Read

May 30 (Reuters) - MOLECULAR PARTNERS AG:

* ‍PROVIDES ADDITIONAL DETAILS ON CLINICAL STUDIES OF PROPRIETARY LEAD ONCOLOGY ASSET MP0250​

* ‍First Patient Dosed in Phase 2 Multiple Myeloma Study​

* ‍IND SUBMISSION TO FDA IN H2 2017 PLANNED FOR MP0250 IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER (EGFR MUT NSCLC)​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below